Diabetes Mellitus, Type 2, Mouth Disease, Obesity, Oral Dysbiosis, PreDiabetes
Conditions
Keywords
Endocannabinoids, Prediabetes, Diabetes Mellitus Type 2, Obesity, Oral Dysbiosis, Oral Disease, Cannabinoids
Brief summary
This study evaluates the relationship of endocannabinoids in saliva with inflammation and oral dysbacteriosis present in people with periodontal disease and prediabetes/type 2 diabetes
Detailed description
Diabetes is a disease that affects millions of people worldwide, and the number of cases is expected to continue to increase in the coming years. Type 2 diabetes (T2D) is the most common form of diabetes and is closely related to prediabetes, a condition in which blood glucose levels are high but not high enough to be diagnosed as diabetes. Both prediabetes and T2D increase the risk of cardiovascular disease and are also associated with diseases of the oral cavity, such as dental caries and periodontal disease. The presence of pathogenic bacteria in the mouth has been linked to these diseases. The endocannabinoid system, a signaling system in the body that regulates various biological processes, has been found to play an important role in energy homeostasis and is implicated in obesity, prediabetes, and T2D. This study seeks to investigate the role of endocannabinoids and related lipids in diseases of the oral cavity in the context of prediabetes and T2D. A bidirectional relationship has been observed between periodontitis and T2D, with inflammation playing a central role in both diseases. Although subtle differences in the microbial composition of the mouth have been identified in people with diabetes, the exact mechanisms remain unclear. Our findings could open up a promising line of research on the therapeutic potential of cannabinoid drugs for the treatment of this type of complications in people with prediabetes/T2D.
Interventions
OTHERObservational study
No intervention will be performed
Sponsors
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Study design
Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
40 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Adults, both sexes (40-65 years) * With obesity and prediabetes: BMI 30-40 and HbA1c 5.7-6.4 * With obesity and diabetes: BMI 30-40 and previous diagnosis of diabetes
Exclusion criteria
* Pregnant women * Diagnosis of some type of neoplasia or treated with radiotherapy and/or chemotherapy in the last year. * Ongoing inflammatory diseases (Crohn's disease, ulcerative colitis, arthritis, etc.) and/or anti-inflammatory treatments * Presence of systemic diseases of vital organs * Participants in treatment with drugs that could alter salivary flow * Smokers * Participants who have not followed the specifications prior to sampling * Participants who did not sign the informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in 2-arachidonoyl-glycerol (2-AG) levels in saliva and plasma | Basal | Measured in pmol/ml |
| Change in N-arachidonoylethanolamine (AEA) levels in saliva and plasma | Basal | Measured in pmol/ml |
| Change in N-palmitoylethanolamine (PEA) levels in saliva and plasma | Basal | Measured in pmol/ml |
| Change in N-oleoylethanolamine (OEA) levels in saliva and plasma | Basal | Measured in pmol/ml |
| Change in N-palmitoylethanolamine (DHEA) levels in saliva and plasma | Basal | Measured in pmol/ml |
| Change in 2-linoleoyl-glycerol (2-LG) levels in saliva and plasma | Basal | Measured in pmol/ml |
| Change in 2-oleoyl-glycerol (2-OG) levels in saliva and plasma | Basal | Measured in pmol/ml |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in vascular endothelial growth factor (VEGF) levels in saliva and plasma | Basal | Measured in pmol/ml |
| Change in Interferon gamma (IFN)-γ levels in saliva and plasma | Basal | Measured in pmol/ml |
| Changes in oral bacteriological profile | Basal | Bacterial 16S rRNA amplicon of the following bacterial strains: Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis, Tannerella forsythia, Treponema denticola, Prevotella intermedia, Fusobacterium nucleatum, Parvimonas micra, Campylobacter rectus, Eikenella corroe, Veillonella parvula and Actinomyces naeslundii for periodontal disease; and Streptococcus mutans, S. sanguis, S. mitior, S. salivarius and S. milleri for dental caries. Unit of Measurement: Fold-increase over reference genes, delta-delta Ct method. |
| Changes in Fasting glucose levels | Basal | Measured in mg/dl |
| Changes in insulin levels | Basal | Measured in mUI/mL |
| Changes from baseline HOMA-IR levels | Basal | HOMA-IR = \[blood insulin (mu/L) × Blood glucose (mmol/L)\]/22.5 |
| Changes from baseline HOMA2-IR levels | Basal | The homeostasis model assessment computational method is used to estimate insulin resistance (HOMA2-IR) from fasting plasma glucose and insulin. The HOMA2-IR is the reciprocal of insulin sensitivity (%S), as a percentage of a normal reference population (normal young adult). A higher score indicates a lower insulin sensitivity. |
| Changes from baseline HOMA2%S levels | Basal | Measured in % |
| Changes from baseline HOMA2%B levels | Basal | Measured in % |
| Changes from baseline QUICKY levels | Basal | QUICKY = 1 / (log(fasting insulin μU/mL) + log(fasting glucose mg/dL)) |
| Changes from baseline HbA1c levels | Basal | Measured in % |
| BMI (body mass index) changes | Basal | Calculated as weight ⁄ height (kg/m2) |
| Change in Tumor necrosis factor alpha (TNF)-α levels in saliva and plasma | Basal | Measured in pmol/ml |
| Changes in waist/hip ratio | Basal | Calculated as waist measurement (cm) divided by hip measurement (cm) (W⁄H) |
| Changes in waist/height ratio | Basal | Calculated as waist measurement (cm) divided by height measurement (cm), (W/He) |
| Changes in blood pressure | Basal | Measured in mmHg |
| Changes in triglycerides | Basal | Measured in mg/dL |
| Changes in total cholesterol | Basal | Measured in mg/dL |
| Changes in HDL cholesterol | Basal | Measured in mg/dL |
| Changes in LDL cholesterol | Basal | Measured in mg/dL |
| Changes in sialometry | Basal | Measured in mL/min |
| Changes in salivary viscosity | Basal | Measured in poise (1 g·(s·cm)-1) |
| Changes in salivary pH | Basal | Logarithm of hydrogen ion concentration |
| Oral health impact profile | Basal | The Oral Health Impact Profile will be assessed by using the OHIP-14sp questionnaire, which is one of the most internationally spread indicators of oral health-related quality of life and it is used to measure the impact of oral conditions on quality of life to complement clinical data in cross-sectional and longitudinal studies. The OHIP-14 is a self-filled questionnaire that focuses on seven dimensions of impact (functional limitation, pain, psychological discomfort, physical disability, psychological disability, social disability and handicap) with participants being asked to respond according to frequency of impact on a 5-point Likert scale coded never (score 0), hardly ever (score 1), occasionally (score2), fairly often (score 3) and very often (score 4) using a twelve-months recall period. |
| Changes in waist circumference | Basal | Measured in cm |
| Change in interleukin-1β levels in saliva and plasma | Basal | Measured in pmol/ml |
| Change in interleukin-6 levels in saliva and plasma | Basal | Measured in pmol/ml |
| Change in interleukin-8 levels in saliva and plasma | Basal | Measured in pmol/ml |
| Change in interleukin-10 levels in saliva and plasma | Basal | Measured in pmol/ml |
| Change in interleukin-17 levels in saliva and plasma | Basal | Measured in pmol/ml |
| Change in leptin levels in saliva and plasma | Basal | Measured in pmol/ml |
Contacts
Primary ContactRodolfo M Ortiz Flores, PhD
Backup ContactFrancisco J Bermúdez-Silva, PhD
Outcome results
None listed